Addressing those two that go together: The angiotensin II receptors and their role in blood-flow regulation

Blood Pressure

Volumn 10, Issue 1, 2001, Pages 6-15

  Fogari, R ^a   de Gasparo, M ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN I; ANTIHYPERTENSIVE AGENT; BRADYKININ; BRADYKININ RECEPTOR; CHYMASE; COLLAGENASE; CYCLIC GMP; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; ESTRADIOL; ESTROGEN; GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; PROSTAGLANDIN; RENIN; STAT PROTEIN; UNINDEXED DRUG; UROTENSIN II; VASOCONSTRICTOR AGENT; VASODILATOR AGENT; VASOPRESSIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; BLOOD FLOW; BLOOD VESSEL TONE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIUM CELL; ENDOTHELIUM LESION; FEEDBACK SYSTEM; HORMONAL REGULATION; HORMONE RECEPTOR INTERACTION; HYPERTENSION; KIDNEY FUNCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SMOOTH MUSCLE FIBER; VASCULAR ENDOTHELIUM; VASCULAR RESISTANCE; VASODILATATION;

EID: 0035070728     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: 10.1080/180-080370501750275839     Document Type: Review

References (93)

1. Tabular view of the morbid appearances in 100 cases connected with albuminous urine with observations
2. Niere und Kreislauf
3. The production of persistent elevation of systolic blood pressure by means of renal ischemia
4. North of England evidence based development project: Guideline for angiotensin converting enzyme inhibitors in primary care management of adults with symptomatic heart failure
5. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients
6. Chymase-dependent angiotensin II forming systems in humans
7. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
8. Preventing CHF
9. Valsartan in heart failure patients previously untreated with an ACE inhibitor
10. A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension
11. Valsartan/hydrochlorothiazide
12. The AT2 receptor: Fact, fancy and fantasy
13. Angiotensin receptors
14. Distribution of the concentrations of angiotensin II (A II), A II receptors, hPL, prolactin, and steroids in human fetal membranes
15. Angiotensin receptor subtypes in the brain
16. Angiotensin II receptors and angiotensin II receptor antagonists
17. The subtype-2 (AT2) angiotensin receptor regulates renal cyclic guanosine 3′, 5′-monophosphate and AT1 receptor-mediated prostaglandin E2 production in conscious rats
18. Bradykinin B2 receptor modulates renal prostaglandin E2 and nitric oxide
19. The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats
20. The subtype 2 angiotensin receptor regulates renal prostaglandin F2 alpha formation in conscious rats
21. Protective role of the angiotensin AT2 receptor in a renal wrap hypertension model
22. Increased renal vasodilator prostanoids prevent hypertension in mice lacking the angiotensin subtype-2 receptor
23. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells
24. Angiotensin II-elicited signal transduction via AT1 receptors in endothelial cells
25. Localization of the ANG II type 2 receptor in the microcirculation of skeletal muscle
26. Hypertension causes premature aging of endothelial function in humans
27. Pathogenetic factors in hypertension. Endothelial factors
28. Endothelial dysfunction and hypertensive vasoconstriction
29. Endothelins and endothelin receptor antagonists : Therapeutic considerations for a novel class of cardiovascular drugs
30. Orphan-receptor ligand human urotensin II: Receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1
31. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14
32. Nitric oxide: Mediator, murderer, and medicine
33. Biology of the endothelium
34. Hypertension as a causative diagnosis of patients entering end-stage renal disease programs in the United States from 1980 to 1986
35. Angiotensin type 2 receptors mediate depressor phase of biphasic pressure response to angiotensin
36. Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice
37. Cardiac-specific overexpression of angiotensin II AT2 receptor causes attenuated response to AT1 receptor-mediated pressor and chronotropic effects
38. Induction of angiotensin II subtype 2 receptor-mediated blood pressure regulation in synthetic diet-fed rats
39. AT(2) receptor stimulation enhances antihypertensive effect of AT(1) receptor antagonist in hypertensive rats
40. Interactions between AT1 and AT2 receptors in uterine arteries from pregnant ewes
41. Opposing actions of angiotensin II on microvascular growth and arterial blood pressure
42. Regulation and role of myocardial collagen matrix remodeling in hypertensive heart disease
43. Angiotensin II receptor blockade attenuates the deleterious effects of exercise training on post-MI ventricular remodeling in rats
44. Angiotensin II stimulates collagen synthesis in human vascular smooth muscle cells. Involvement of the AT(1) receptor, transforming growth factor-beta, and tyrosine phosphorylation
45. Chronic AT(1) blockade stimulates extracellular collagen type I degradation and reverses myocardial fibrosis in spontaneously hypertensive rats
46. The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: Gain-of-function study using gene transfer
47. Role of type 1 and type 2 angiotensin receptors in angiotensin II-induced cardiomyocyte hypertrophy
48. Interferon regulatory factor-1 up-regulates angiotensin II type 2 receptor and induces apoptosis
49. Angiotensin II induces apoptosis of human endothelial cells. Protective effect of nitric oxide
50. Modulation of the vascular smooth muscle angiotensin subtype 2 (AT2) receptor by angiotensin II
51. Modulation of the AT2 subtype receptor gene activation and expression by the AT1 receptor in endothelial cells
52. Angiotensin II induces ovulation and oocyte maturation in rabbit ovaries via the AT2 receptor subtype
53. Mechanisms responsible for endothelial dysfunction associated with acute estrogen deprivation in normotensive women
54. Menopause is associated with endothelial dysfunction in women
55. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study
56. AT1 receptor blocker improves pressure-overload induced cardiac remodeling via at1 receptor inhibition and AT2 receptor stimulation: Study using AT2 receptor null mice
57. Evidence for angiotensin II type 2 receptor-mediated cardiac myocyte enlargement during in vivo pressure overload
58. Stimulation of different subtypes of angiotensin II receptors, AT1 and AT2 receptors, regulates STAT activation by negative crosstalk
59. Increased cardiac angiotensin II levels induce right and left ventricular hypertrophy in normotensive mice
60. AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism
61. Angiotensin type 2 receptor mediates valsartan-induced hypotension in conscious rats
62. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation
63. The growth-dependent expression of angiotensin II type 2 receptor is regulated by transcription factors interferon regulatory factor-1 and -2
64. Inflammation influences vascular remodeling through AT2 receptor expression and signaling
65. Angiotensin II and bradykinin regulate the expression of P-selection on the surface of endothelial cells in culture
66. Angiotensin II-induced leukocyte adhesion on human coronary endothelial cells is mediated by E-selectin
67. Safety of the combination of valsartan and benazeprilin patients with chronic renal disease
68. Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension
69. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist Iosartan
70. Effect of ACE inhibition on endothelial dysfunction in patients with chronic heart failure
71. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease
72. Converting enzyme inhibitor improves forearm reactive hyperemia in essential hypertension
73. AT(1) receptor antagonism reduces endothelial dysfunction and intimal thickening in atherosclerotic rabbits
74. Combination of non-hypotensive doses of valsartan and enalapril improves survival of spontaneously hypertensive rats with endothelial dysfunction
75. Valsartan. A review of its pharmacology and therapeutic use in essential hypertension
76. Pharmacological and clinical profile of valsartan
77. Angiotensin II receptor subtypes in the human renal cortex and renal cell carcinoma
78. Presence of angiotensin II AT2 receptor binding sites in the adventitia of human kidney vasculature
79. Regulation of the renal angiotensin II receptor gene in acute unilateral ureteral obstruction
80. Mechanism of ochratoxin A-induced reduction of glomerular filtration rate in rats
81. Effect of indomethacinon the renal response to angiotensin II receptor blockade in healthy subjects
82. Sexual activity in hypertensive men treated with valsartan or carvedilol. A crossover study
83. A human homolog of angiotensin converting enzyme-Cloning and functional expression as a captopril insensitive carboxypeptidase
84. Tissue angiotensin II as a modulator of erectile function. I. Angiotensin peptide content, secretion and effects in the corpus cavernosum
85. Effects of angiotensin II on sexual function, blood pressure, and fluid intake are differentially affected by AT-1 receptor blockade
86. A possible role for angiotensin II in the regulation of male sexual behavior in rats
87. Sexual function in hypertensive males treated with lisinopril or atenolol: A cross-over study
88. Sexual dysfunction in the United States: Prevalence and predictors
89. Compliance to treatment
90. Improving outcomes in CHF: Val-HeFT. Valsartan in Heart Failure Trial
91. Rationale and design of the Valsartan Heart Failure Trial: A large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic CHF
92. Candesartan in heart failure-Assessment of reduction in mortality and morbidity (CHARM): Rationale and design
93. Enhancing cardiac protection after myocardial infarction: Rationale for newer clinical trials of angiotensin receptor blockers